# JPMorgan Chase

Type: Company (JPM)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/jpmorgan-chase
Canonical HTML page: https://getbiobrief.com/entity/jpmorgan-chase

## Timeline

- **2026-04-14**: JPM Earnings — JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
- **2026-04-10**: FDA Decision Date — Expected regulatory ruling on orforglipron oral weight loss drug.
- **2023**: Zepbound Approval — FDA expands tirzepatide approval to include chronic weight management.
- **2022**: Mounjaro Launch — Tirzepatide enters the market for Type 2 Diabetes treatment.

## Recent coverage (2 stories)

### $12B Bet on AGI Drug Design: Bezos’s Prometheus Targets Biotech Manufacturing
2026-06-12 02:52:28 · Sentiment: Very Bullish · Impact: 9/10 · Sources: 2

Prometheus's $12B raise envisions an artificial general engineer that can design drug compounds autonomously, potentially cutting years from pharmaceutical R&D. The startup's biotech roots via co-founder Vik Bajaj of Verily add credibility.
Full story: https://getbiobrief.com/story/bio-prometheus-12b-drugs

### Eli Lilly Faces Critical April 10 FDA Decision on Oral Weight Loss Candidate
2026-03-23 00:14:59 · Sentiment: Bullish · Impact: 7/10 · Sources: 5

Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Full story: https://getbiobrief.com/story/eli-lilly-orforglipron-fda-decision-april-catalyst

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.